Clinically assessing cognitive function in Parkinson's disease

Megan Bakeberg, Maddeson Riley, Michelle Byrnes, Frank L. Mastaglia, Ryan S. Anderton

Research output: Chapter in Book/Conference paperChapterpeer-review

Abstract

Although Parkinson's disease (PD) is typically framed as a motor disorder, people with the disease may experience a plethora of other nonmotor symptoms that may be equally debilitating. The management of cognitive impairment is an area of growing clinical interest given its heterogeneous manifestations and the increased relative risk of dementia; hence there is an urgent need to be able to effectively assess cognitive function and identify patients in the early stages of cognitive deterioration. Cognitive impairment is frequently reported at the time of PD diagnosis, with executive, attentional, and visuospatial abilities being primarily affected. Formal cognitive assessments are the most efficient, comprehensive, and reliable way to confirm the presence of early cognitive symptoms in PD. However, there are an array of varying evaluative tools with diverse strengths and weaknesses, and the reliability of cognitive evaluations can be clouded by associated symptoms, level of education, and reproducibility of the procedures over time. As such, the selection of the most relevant, reliable, and sensitive protocols for cognitive assessment is imperative. Research endeavors continue to identify more reliable and discriminating protocols as well as biomarkers that will allow earlier diagnosis of cognitive and behavioral deficits and the accurate assessment of new therapeutic approaches to delay or stop their progression.
Original languageEnglish
Title of host publicationDiagnosis and Management in Parkinson's Disease
EditorsColin R. Martin, Victor R. Preedy
Place of PublicationUK
PublisherAcademic Press
Chapter24 / Part II
Pages409-423
Volume1
ISBN (Print)9780128159460
DOIs
Publication statusPublished - 2020

Fingerprint

Dive into the research topics of 'Clinically assessing cognitive function in Parkinson's disease'. Together they form a unique fingerprint.

Cite this